These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Regression of subependymal giant cell astrocytomas with RAD001 (Everolimus) in tuberous sclerosis complex. Yalon M; Ben-Sira L; Constantini S; Toren A Childs Nerv Syst; 2011 Jan; 27(1):179-81. PubMed ID: 20703486 [TBL] [Abstract][Full Text] [Related]
5. Potential of mTOR inhibitors for the treatment of subependymal giant cell astrocytomas in tuberous sclerosis complex. Major P Aging (Albany NY); 2011 Mar; 3(3):189-91. PubMed ID: 21415462 [TBL] [Abstract][Full Text] [Related]
6. Long-term effect of everolimus on epilepsy and growth in children under 3 years of age treated for subependymal giant cell astrocytoma associated with tuberous sclerosis complex. Kotulska K; Chmielewski D; Borkowska J; Jurkiewicz E; Kuczyński D; Kmieć T; Łojszczyk B; Dunin-Wąsowicz D; Jóźwiak S Eur J Paediatr Neurol; 2013 Sep; 17(5):479-85. PubMed ID: 23567018 [TBL] [Abstract][Full Text] [Related]
7. Pathogenesis of tuberous sclerosis subependymal giant cell astrocytomas: biallelic inactivation of TSC1 or TSC2 leads to mTOR activation. Chan JA; Zhang H; Roberts PS; Jozwiak S; Wieslawa G; Lewin-Kowalik J; Kotulska K; Kwiatkowski DJ J Neuropathol Exp Neurol; 2004 Dec; 63(12):1236-42. PubMed ID: 15624760 [TBL] [Abstract][Full Text] [Related]
8. Differentiating the mTOR inhibitors everolimus and sirolimus in the treatment of tuberous sclerosis complex. MacKeigan JP; Krueger DA Neuro Oncol; 2015 Dec; 17(12):1550-9. PubMed ID: 26289591 [TBL] [Abstract][Full Text] [Related]
9. Successful everolimus therapy for SEGA in pediatric patients with tuberous sclerosis complex. Cappellano AM; Senerchia AA; Adolfo F; Paiva PM; Pinho R; Covic A; Cavalheiro S; Saba N Childs Nerv Syst; 2013 Dec; 29(12):2301-5. PubMed ID: 23743818 [TBL] [Abstract][Full Text] [Related]
10. Everolimus for subependymal giant cell astrocytoma in patients with tuberous sclerosis complex: 2-year open-label extension of the randomised EXIST-1 study. Franz DN; Belousova E; Sparagana S; Bebin EM; Frost M; Kuperman R; Witt O; Kohrman MH; Flamini JR; Wu JY; Curatolo P; de Vries PJ; Berkowitz N; Anak O; Niolat J; Jozwiak S Lancet Oncol; 2014 Dec; 15(13):1513-1520. PubMed ID: 25456370 [TBL] [Abstract][Full Text] [Related]
11. Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. Krueger DA; Care MM; Holland K; Agricola K; Tudor C; Mangeshkar P; Wilson KA; Byars A; Sahmoud T; Franz DN N Engl J Med; 2010 Nov; 363(19):1801-11. PubMed ID: 21047224 [TBL] [Abstract][Full Text] [Related]
12. Mammalian target of rapamycin inhibitors for intractable epilepsy and subependymal giant cell astrocytomas in tuberous sclerosis complex. Cardamone M; Flanagan D; Mowat D; Kennedy SE; Chopra M; Lawson JA J Pediatr; 2014 May; 164(5):1195-200. PubMed ID: 24518170 [TBL] [Abstract][Full Text] [Related]
14. Is mTOR inhibition a systemic treatment for tuberous sclerosis? Moavero R; Coniglio A; Garaci F; Curatolo P Ital J Pediatr; 2013 Sep; 39():57. PubMed ID: 24044547 [TBL] [Abstract][Full Text] [Related]
15. Presurgical Administration of mTOR Inhibitors in Patients with Large Subependymal Giant Cell Astrocytoma Associated with Tuberous Sclerosis Complex. Jiang T; Du J; Raynald ; Wang J; Li C World Neurosurg; 2017 Nov; 107():1053.e1-1053.e6. PubMed ID: 28866062 [TBL] [Abstract][Full Text] [Related]
16. Everolimus (RAD001): first systemic treatment for subependymal giant cell astrocytoma associated with tuberous sclerosis complex. Józwiak S; Stein K; Kotulska K Future Oncol; 2012 Dec; 8(12):1515-23. PubMed ID: 23231513 [TBL] [Abstract][Full Text] [Related]
17. Congenital subependymal giant cell astrocytomas in patients with tuberous sclerosis complex. Kotulska K; Borkowska J; Mandera M; Roszkowski M; Jurkiewicz E; Grajkowska W; Bilska M; Jóźwiak S Childs Nerv Syst; 2014 Dec; 30(12):2037-42. PubMed ID: 25227171 [TBL] [Abstract][Full Text] [Related]
18. Response of subependymal giant cell astrocytoma with spinal cord metastasis to everolimus. Aguilera D; Flamini R; Mazewski C; Schniederjan M; Hayes L; Boydston W; Castellino RC; MacDonald TJ J Pediatr Hematol Oncol; 2014 Oct; 36(7):e448-51. PubMed ID: 24276039 [TBL] [Abstract][Full Text] [Related]
19. EFFECTS: an expanded access program of everolimus for patients with subependymal giant cell astrocytoma associated with tuberous sclerosis complex. Fogarasi A; De Waele L; Bartalini G; Jozwiak S; Laforgia N; Verhelst H; Petrak B; Pedespan JM; Witt O; Castellana R; Crippa S; Gislimberti G; Gyorsok Z BMC Neurol; 2016 Aug; 16():126. PubMed ID: 27502586 [TBL] [Abstract][Full Text] [Related]
20. Response to everolimus is seen in TSC-associated SEGAs and angiomyolipomas independent of mutation type and site in TSC1 and TSC2. Kwiatkowski DJ; Palmer MR; Jozwiak S; Bissler J; Franz D; Segal S; Chen D; Sampson JR Eur J Hum Genet; 2015 Dec; 23(12):1665-72. PubMed ID: 25782670 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]